Skip to main content

NASDAQ:PSTI - Pluristem Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.88
  • Forecasted Upside: 170.55 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.65
▲ +0.11 (3.11%)
1 month | 3 months | 12 months
Get New Pluristem Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PSTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PSTI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$9.88
▲ +170.55% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pluristem Therapeutics in the last 3 months. The average price target is $9.88, with a high forecast of $12.50 and a low forecast of $6.00. The average price target represents a 170.55% upside from the last price of $3.65.

Buy

The current consensus among 4 polled investment analysts is to buy stock in Pluristem Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2021Alliance Global PartnersInitiated CoverageBuy$12.50N/A
i
5/4/2021Alliance Global PartnersInitiated CoverageBuy$12.50Low
i
12/10/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$6.00High
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
12/7/2020HC WainwrightReiterated RatingBuy$15.50 ➝ $9.00High
i
Rating by S. Ramakanth at HC Wainwright
10/9/2020Dawson JamesReiterated RatingBuy$12.00Low
i
7/24/2020Jefferies Financial GroupBoost Price TargetBuy$12.00 ➝ $16.00Medium
i
Rating by Chris Howerton at Jefferies Financial Group Inc.
6/19/2020Jefferies Financial GroupInitiated CoverageBuy$12.00High
i
5/15/2020Maxim GroupReiterated RatingBuy$12.00Low
i
Rating by Jason McCarthy at Maxim Group
5/14/2020HC WainwrightReiterated RatingBuy$15.50Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/15/2020Dawson JamesReiterated RatingBuyHigh
i
Rating by Jason Kolbert at Dawson James
4/14/2020Maxim GroupInitiated CoverageBuy$12.00High
i
Rating by Jason McCarthy at Maxim Group
4/8/2020Maxim GroupInitiated CoverageBuy$8.00High
i
Rating by Jason McCarthy at Maxim Group
3/31/2020Maxim GroupInitiated CoverageBuy$8.00Medium
i
Rating by Jason McCarthy at Maxim Group
3/18/2020Maxim GroupReiterated RatingBuy$8.00High
i
2/10/2020HC WainwrightReiterated RatingBuy$15.50Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/16/2019Dawson JamesInitiated CoverageBuy$12.00High
i
12/4/2019Maxim GroupReiterated RatingBuy$8.00Low
i
11/13/2019Maxim GroupReiterated RatingBuy$8.00High
i
11/13/2019HC WainwrightReiterated RatingBuy$15.50High
i
7/22/2019LADENBURG THALM/SH SHInitiated CoverageBuy ➝ BuyLow
i
4/24/2019Maxim GroupReiterated RatingBuy$30.00Low
i
Rating by Jason McCarthy at Maxim Group
12/17/2018Maxim GroupSet Price TargetBuy$30.00Medium
i
Rating by Jason McCarthy at Maxim Group
12/17/2018HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/4/2018Maxim GroupSet Price TargetBuy$30.00High
i
Rating by Jason McCarthy at Maxim Group
11/28/2018Maxim GroupReiterated RatingBuy$30.00High
i
Rating by Jason McCarthy at Maxim Group
11/12/2018HC WainwrightSet Price TargetBuy$40.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/28/2018HC WainwrightReiterated RatingBuy$35.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/31/2018B. RileyInitiated CoverageBuy$45.00Low
i
Rating by G. Zavoico at B. Riley
5/11/2018HC WainwrightSet Price TargetBuy$40.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/10/2018Maxim GroupSet Price TargetBuy$30.00Low
i
Rating by Jason McCarthy at Maxim Group
5/1/2018HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/30/2018Maxim GroupSet Price TargetBuy$30.00High
i
Rating by Jason McCarthy at Maxim Group
4/23/2018Maxim GroupReiterated RatingBuy$30.00Low
i
Rating by Jason McCarthy at Maxim Group
2/21/2018Maxim GroupSet Price TargetBuy$30.00Medium
i
Rating by Jason Kolbert at Maxim Group
1/16/2018HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/9/2017HC WainwrightReiterated RatingBuy$35.00N/A
i
Rating by S. Ramakanth at HC Wainwright
11/1/2017Maxim GroupSet Price TargetBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/26/2017Maxim GroupSet Price TargetBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/19/2017Maxim GroupSet Price TargetBuy$20.00N/A
i
Rating by Jason Kolbert at Maxim Group
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$50.00N/A
i
Rating by V. Bernardino at Seaport Global Securities
10/2/2017Maxim GroupSet Price TargetBuy$20.00Low
i
Rating by Jason Kolbert at Maxim Group
9/19/2017HC WainwrightReiterated RatingBuy$35.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/6/2017HC WainwrightReiterated RatingBuy$35.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/5/2017Maxim GroupReiterated RatingBuy$20.00Medium
i
Rating by Jason Kolbert at Maxim Group
8/17/2017HC WainwrightSet Price TargetBuy$40.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/16/2017Maxim GroupSet Price TargetBuy$20.00Medium
i
Rating by Jason Kolbert at Maxim Group
7/10/2017Maxim GroupSet Price TargetBuy$20.00High
i
Rating by Jason Kolbert at Maxim Group
6/19/2017Maxim GroupUpgradeHold ➝ Buy$20.00Low
i
Rating by Jason Kolbert at Maxim Group
5/22/2017Maxim GroupReiterated RatingHoldLow
i
Rating by Jason Kolbert at Maxim Group
5/15/2017HC WainwrightReiterated RatingBuy$35.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/5/2017HC WainwrightReiterated RatingBuy$35.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/4/2017Maxim GroupReiterated RatingHoldLow
i
Rating by Jason Kolbert at Maxim Group
2/13/2017Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason Kolbert at Maxim Group
2/11/2017HC WainwrightSet Price TargetBuy$40.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/17/2017Maxim GroupSet Price TargetBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
1/10/2017(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
12/23/2016(FBRC)Reiterated RatingOutperform$60.00N/A
i
Rating by Vernon Bernardino at (FBRC)
11/2/2016Maxim GroupSet Price TargetBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
9/12/2016Maxim GroupReiterated RatingBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
8/4/2016HC WainwrightReiterated RatingBuy$35.00N/A
i
7/27/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
7/19/2016HC WainwrightReiterated RatingBuy$35.00N/A
i
Rating by S. Ramakanth at HC Wainwright
7/11/2016Maxim GroupReiterated RatingBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
7/11/2016(FBRC)Reiterated RatingBuyN/A
i
Rating by Vernon Bernardino at (FBRC)
6/22/2016Maxim GroupReiterated RatingBuy$30.00N/A
i
Rating by Jason Kolbert at Maxim Group
6/22/2016(FBRC)Reiterated RatingOutperform$60.00N/A
i
Rating by Vernon Bernardino at (FBRC)
5/16/2016Maxim GroupReiterated RatingBuyN/A
i
Rating by Jason Kolbert at Maxim Group
(Data available from 5/16/2016 forward)
Pluristem Therapeutics logo
Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Read More

Today's Range

Now: $3.65
$3.51
$3.84

50 Day Range

MA: $4.40
$3.54
$5.04

52 Week Range

Now: $3.65
$3.50
$12.15

Volume

284,624 shs

Average Volume

647,958 shs

Market Capitalization

$115.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Pluristem Therapeutics?

The following Wall Street analysts have issued stock ratings on Pluristem Therapeutics in the last twelve months: Alliance Global Partners, Dawson James, HC Wainwright, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for PSTI.

What is the current price target for Pluristem Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Pluristem Therapeutics in the last year. Their average twelve-month price target is $9.88, suggesting a possible upside of 170.5%. Alliance Global Partners has the highest price target set, predicting PSTI will reach $12.50 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $6.00 for Pluristem Therapeutics in the next year.
View the latest price targets for PSTI.

What is the current consensus analyst rating for Pluristem Therapeutics?

Pluristem Therapeutics currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PSTI will outperform the market and that investors should add to their positions of Pluristem Therapeutics.
View the latest ratings for PSTI.

What other companies compete with Pluristem Therapeutics?

How do I contact Pluristem Therapeutics' investor relations team?

Pluristem Therapeutics' physical mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 3508409. The biotechnology company's listed phone number is 972747108600 and its investor relations email address is [email protected] The official website for Pluristem Therapeutics is www.pluristem.com.